Oragenics
高管
查看带有其 11 名主要高管的组织结构图
Oragenics 搜索最多的简介
- Charles Pope, Interim Chief Executive Officer and Chairman of the ...
- Alan Dunton, Director
- Kimberly Murphy, Director
高管在Oragenics变化
- William Peacock已作为Chief Clinical Officer加入公司 (新闻发布的2024五月23号).
- James Kelly已作为Chief Medical Officer加入公司 (新闻发布的2024三月19号).
- Charles Pope 曾任 Chairman of the Board, 现升职为 Interim Chief Executive Officer and Chairman of the Board (新闻发布的2024二月13号).
创建提醒
跟踪 Oragenics 的高管变动
生物技术
Oragenics 拥有 2,317 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Evommune 刚刚宣布为 115 筹款数百万美元。 (公布2024十一月4号).
- AgomAb Therapeutics 刚刚宣布为 89 筹款数百万美元。 (公布2024十月29号).
- Seaport Therapeutics 刚刚宣布为 225 筹款数百万美元。 (公布2024十月25号).
生物技术 行业的其他推荐联系人
消息
Oragenics 的最新新闻稿
- Oragenics, Inc. Announces Closing of Public Offering :: Oragenics, Inc. (OGEN)
- Oragenics, Inc. Announces Pricing of Public Offering :: Oragenics, Inc. (OGEN)
- Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients :: Oragenics, Inc. (OGEN)
- Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing :: Oragenics, Inc. (OGEN)
- Oragenics Improves Intranasal Drug Formulation for Treating Concussed Patients :: Oragenics, Inc. (OGEN)
- Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer :: Oragenics, Inc. (OGEN)
- Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial :: Oragenics, Inc. (OGEN)
- Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia :: Oragenics, Inc. (OGEN)
- Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine :: Oragenics, Inc. (OGEN)
- Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards :: Oragenics, Inc. (OGEN)
- View more press releases Close
关于 Oragenics 的社交媒体
保持联系
通过电子邮件联系联系该企业高管，包括 Charles Pope 
